Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
October 16, 2024 16:15 ET
|
OncoCyte Corporation
Oncocyte Announces Participation in the LD Micro Main Event XVII
Conference in Los Angeles
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
October 08, 2024 08:30 ET
|
OncoCyte Corporation
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO...
Oncocyte Signs Leading Transplant Centers in US and Germany
October 02, 2024 18:41 ET
|
OncoCyte Corporation
GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volumeCompany clears first stage gate in clinical product development process and has...
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
October 02, 2024 18:35 ET
|
OncoCyte Corporation
IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a...
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
August 12, 2024 16:10 ET
|
OncoCyte Corporation
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results
August 08, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte Announces Successful GraftAssureTM Beta Launch and Q2 2024 Results
Oncocyte Announces August Investor Conferences Participation
August 05, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte Announces August Investor Conferences Participation
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
August 01, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
Oncocyte Appoints Andrea James as Chief Financial Officer
June 17, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte Appoints Seasoned Finance Executive Andrea James as Chief Financial Officer
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
May 30, 2024 16:47 ET
|
OncoCyte Corporation
Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with...